Finerenone Cuts Cardiorenal Risk 23% in Nondiabetic CKD, Slowing eGFR Decline by 0.7
Updated
Updated · DocWire News · Jun 10
Finerenone Cuts Cardiorenal Risk 23% in Nondiabetic CKD, Slowing eGFR Decline by 0.7
3 articles · Updated · DocWire News · Jun 10
Summary
Phase 3 FIND-CKD data in more than 1,500 nondiabetic CKD patients showed finerenone significantly slowed annual eGFR decline by 0.7 mL/min/1.73 m² versus placebo, meeting the trial’s primary endpoint.
The drug also cut the composite risk of kidney failure, major sustained eGFR loss, heart-failure hospitalization or cardiovascular death by 23%, with a hazard ratio of 0.77.
Standard care in the trial included maximally tolerated renin-angiotensin system blockade, and investigators said benefits were consistent across prespecified CKD subgroups.
hyperkalemia was more frequent with finerenone, but few cases caused discontinuation or hospitalization, no new safety signals emerged, and acute kidney injury rates were similar to placebo.
The results, presented at the European Renal Association Congress and published in the New England Journal of Medicine, extend finerenone’s evidence base beyond diabetic CKD.
A life-saving kidney drug is proven effective, so why might millions of patients never receive it?
Finerenone slows kidney failure, but what is the hidden cost for patients and healthcare systems?
FDA Approval of Finerenone (Kerendia) in 2025: A Breakthrough for Heart Failure with Preserved Ejection Fraction and Cardiorenal Protection
Overview
In July 2025, the FDA approved Kerendia (finerenone) for adults with heart failure who have a left ventricular ejection fraction of 40% or greater, a group known as HFpEF or HFmrEF. This approval is a major step forward because these patients previously had few effective treatments. Supported by recent research, finerenone offers a new therapeutic option for this underserved population. Its introduction marks a crucial advance in heart failure care, expanding choices for patients who need better solutions and reflecting ongoing progress in cardiovascular medicine.